PhytoHealth CEO Angel Lee earns industry recognition for the development of PG2, a breakthrough botanical treatment for cancer-related fatigue, bolstering the company's clinical profile.
PhytoHealth's CEO receives an award for developing the first prescription drug for cancer-related fatigue, highlighting the company's innovative pipeline and positive recognition.
PhytoHealth Corporation CEO Angel Lee has been honored for her leadership in advancing PG2, Taiwan's first approved botanical drug. The recognition underscores the company's role in addressing cancer-related fatigue and its ongoing commitment to medical innovation in the oncology sector.
PG2 is Taiwan's first approved botanical drug specifically designed to treat cancer-related fatigue, marking a milestone in supportive oncology care.